Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Acute Myeloid Leukemia
Azacitidine Maintenance Confers Benefits in AML Regardless of FLT3, NPM1 Status
Oral azacitidine improved survival independent of NPM1 or FLT3 mutational status, cytogenetic risk, or MRD status after chemotherapy.
Racial Disparities Identified in AYA Patients With Acute Myeloid Leukemia
Among AYAs with AML, Black patients experience higher rates of early death and lower rates of overall survival than White patients.
Detection of FLT3-ITD MRD Is Associated With Relapse and Death in AML
FLT3-ITD minimal residual disease is associated with an increased risk of relapse and death in patients with acute myeloid leukemia.
Though Improved, Outcomes Remain Poor for Patients With MDS Who Progress on HMA Therapy
Researchers sought to determine outcomes in patients with MDS whose disease progressed during treatment with hypomethylating agents.
Midostaurin Maintenance Improved Survival in FLT3-Mutated Acute Myeloid Leukemia
Researchers sought to determine the efficacy of midostaurin maintenance therapy in patients with FLT3-mutated acute myeloid leukemia.
Integrating KMT2A-PTD into DNA NGS to Predict Outcomes in AML, MDS
Integrating the assessment of KMT2A-PTD into standard DNA sequencing may be prognostically valuable for patients with MDS or AML.
Adding Idasanutlin to Cytarabine Does Not Improve OS in Relapsed/Refractory AML
Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.
Similar OS, More Infections With CPX-351 vs Venetoclax Plus Azacitidine
Researchers found similar survival, but more infections and longer hospitalizations, with CPX-351 vs venetoclax plus azacitidine.
Enasidenib in Relapsed/Refractory IDH2-Mutated Acute Myeloid Leukemia
Enasidenib did not improve overall survival, but it was associated with improvements in event-free survival and time to treatment failure.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...